Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer

Prostate

Volumn 68, Issue 8, 2008, Pages 803-808

  Kang, Su Cho ^a   Joong, Shik Lee ^b   Nam, Hoon Cho ^a   Park, Kyeongmee ^c   Won, Sik Ham ^a   Young, Deuk Choi ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Catholic Kwandong University   (South Korea)

^c Inje University College of Medicine   (South Korea)

Author keywords

erbB 1; erbB 2; Genes; Mutation; Prostatic neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SAMPLING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DNA MUTATIONAL ANALYSIS; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 45349087172     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20743     Document Type: Article

References (22)

1. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005;23(1):1-9.
2. Hellawell GO, Brewster SF. Growth factors and their receptors in prostate cancer. BJU Int 2002;89(3):230-240.
3. Bartlett JM, Brawley D, Grigor K, Munro AF, Dunne B, Edwards J. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J Pathol 2005;205(4):522-529.
4. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8(11):3438-3444.
5. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004;90(2):449-454.
6. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001;7(9):2643-2647.
7. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ. Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001;166(4): 1514-1519.
8. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92(23):1918-1925.
9. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23(3):455-460.
10. Formento P, Hannoun-Levi JM, Fischel JL, Magne N, Etienne-Grimaldi MC, Milano G. Dual HER 1-2targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. Eur J Cancer 2004;40(18):2837-2844.
11. Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V, Cittadini A. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 2004;201(1): 97-105.
12. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist 2002;7 (Suppl 4):31-39.
13. Janne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, Distel RJ, Meyerson M, Johnson BE. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006;12(3 Pt 1):751-758.
14. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97(5):339-346.
15. Skacel M, Ormsby AH, Pettay JD, Tsiftsakis EK, Liou LS, Klein EA, Levin HS, Zippe CD, Tubbs RR. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: A differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Hum Pathol 2001; 32(12):1392-1397.
16. Cui J, Deubler DA, Rohr LR, Zhu XL, Maxwell TM, Changus JE, Brothman AR. Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. Cancer Genet Cytogenet 1998;107(1):51-60.
17. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59(4):803-806.
18. Kaltz-Wittmer C, Klenk U, Glaessgen A, Aust DE, Diebold J, Lohrs U, Baretton GB. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 2000; 80(9):1455-1464.
19. Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP Jr, Fisher HA, Rifkin MD, Muraca PJ. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997;79(11):2162-2170.
20. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(3 Pt 1):839-844.
21. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregore V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97(9):643-655.
22. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-144.